ORIGINAL ARTICLE

Synthesis of 1,2,4-triazole derivatives containing benzothiazoles as pharmacologically active molecule

Navin B. Patel, and Imran H. Khan

Department of Chemistry, Veer Narmad South Gujarat University, Surat, Gujarat, India

Abstract

In attempt to make significant pharmacologically active molecule, we report here the synthesis and *in vitro* antimicrobial and antitubercular activity of various series of 3-(3-pyridyl)-5-(4-nitrophenyl)-4-(*N*-substituted-1,3-benzothiazol-2-amino)-4*H*-1,2,4-triazole. The antimicrobial activity of title compounds were examined against two Gram-positive bacteria (*Staphylococcus aureus, Streptococcus pyogenes*), two Gram-negative bacteria (*Escherichia coli, Pseudomonas aeruginosa*), and three fungi (*Candida albicans, Aspergillus niger, Aspergillus clavatus*) using the broth microdilution method and antitubercular activity H₃₇Rv using Lowenstein-Jensen agar method.

Keywords: 1,2,4-Triazole, antimicrobial activity, antitubercular activity

Introduction

Tuberculosis (TB) is the leading infectious cause of death in the world today, with ~3 million deceasing every year. An increase in the global burden of TB with the worldwide mortality rate of 23% is a major concern in the socioeconomic and health sectors.¹⁻⁵ The synergy of this disease with HIV infection and the emergence of multidrug resistance and extensively drug resistance tuberculosis (MDRTB and XDRTB) pose a threatening global challenge.⁶⁻⁸ Although a number of lead molecules exist today to develop new drugs, no new chemical entity has emerged for clinical use for over the last 45 years in the treatment of this disease.^{9,10} Therefore, there is an urgent need to develop new drugs, acting through a novel mechanism of action for the chemotherapy of TB.

Recently, certain triazole-based compounds were reported to possess antimicrobial activities.¹¹⁻¹³ It is believed that aryl-azolyl-ethane moiety, present in many azole antifungal drugs, serves as pharmacophore in compounds having *Mycobacterium* killing activity.^{14,15} Many azole derivatives have also been shown to possess interesting antimycobacterial activity in addition to antifungal activity.¹⁶⁻¹⁸ In addition, closer analogues of our oxadiazole were reported to possess antitubercular activity.^{19,20} It is established that these compounds target the sterol demethylase, a mixed-function oxidase involved in sterol synthesis in eukaryotic organisms.²¹ The unraveling of *Mycobacterium* genome sequence has revealed that a protein having homology to one of the above mixed oxidase function is present in *Mycobacterium tuberculosis*.²² In view of this data, we aimed the synthesis, antimicrobial, and antitubercular evaluation of new substituted 1,2,4-triazole derivatives. We have incorporated triazoles with pyridine and benzothiazole derivatives, which possess wide variety of biological activity.

Experimental section

Chemistry

All chemicals were of analytical grade and use directly. All melting points were determined in PMP-DM scientific melting point apparatus and are uncorrected. The completion of the reaction was checked by TLC using Merck silica gel 60 F254 and spots were visualized under UV radiation. IR spectra were recorded on Perkin-Elmer RX 1 FT-IR spectrophotometer in KBr (γ_{max} in cm⁻¹). ¹H

Address for Correspondence: Navin B. Patel, Department of Chemistry, Veer Narmad South Gujarat University, Surat-395007, Gujarat, India. E-mail: drnavin@satyam.net.in

⁽Received 08 March 2010; revised 25 July 2010; accepted 24 October 2010)

NMR spectra were recorded in CDCl₃ on a Bruker Avance II 400 NMR spectrometer (400 MHz) using TMS as internal standard (δ in ppm). ¹³C NMR spectra were recorded in CDCl₃ on a Bruker Avance II 400 NMR spectrometer operating at 400 MHz (δ in ppm). The microanalyses were performed on a Heraeus Carlo Erba 1180 CHN analyzer. The mass spectra were recorded on micromass Q-T of micro (TOF MS ES+).

Substituted 2-hydrazino-1,3-benzothiazole (2a-j) was prepared by the literature procedure.^{23,24}

General procedure for synthesis of 2-hydrazino benzothiazoles

(2a-j). Concentrated hydrochloric acid (0.067 mol) was added drop wise with stirring to hydrazine hydrate (0.12 mol) at 5–6°C followed by ethylene glycol (30 mL); thereafter substituted 2-amino-1,3-benzothiazole (1a-j) (20 mmol) was added in portions and the resultant mixture was refluxed for 2–3 h and cooled at room temperature. The reaction progress was monitored by TLC using toluene:ethylacetate (75:25) as mobile phase. The reaction mixture was filtered and resulting precipitate was washed with distilled water. The resulting crude was crystallized from ethanol. The other compounds of the series were prepared by similar procedure.

(2a). Yield 70%: m.p. 204–206°C. IR (KBr): 3435 (NH₂), 3200 (NH), 1631 (C=N), 1442 (thiazole) cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 4.83 (s, 2H, NH₂, disappeared on D₂O exchange), 8.94 (s, 1H, NH, disappeared on D₂O exchange), 7.28–7.64 (m, 3H, 3CH) ppm. Anal. calcd. for C₇H₆N₃FS: C, 45.89; H, 3.30; N, 22.94; Found: C, 45.91; H, 3.31; N, 22.98%.

(2b). Yield 61%; m.p. 200–202°C; IR (KBr): 3449 (NH₂), 3212 (NH), 1623 (C=N), 1451 (thiazole) cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 4.83 (s, 2H, NH₂, disappeared on D₂O exchange), 8.90 (s, 1H, NH, disappeared on D₂O exchange), 7.63–7.93 (m, 3H, 3CH) ppm. Anal. calcd. for C₇H₆N₃SBr: C, 34.44; H, 2.48; N, 17.21; Found: C, 34.40; H, 2.45; N, 17.19%.

(2c). Yield 67%; m.p. 210–212°C; IR (KBr): 3445 (NH₂), 3220 (NH), 1640 (C=N), 1448 (thiazole) cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 4.81 (s, 2H, NH₂, disappeared on D₂O exchange), 8.92 (s, 1H, NH, disappeared on D₂O exchange), 7.04–7.79 (m, 3H, 3CH) ppm. Anal. calcd. for C₇H₆N₄O₂S: C, 40.00; H, 2.88; N, 26.65; Found: C, 39.97; H, 2.90; N, 26.68%.

(2d). Yield 62%; m.p. 198–200°C; IR (KBr): 3449 (NH₂), 3222 (NH), 1620 (C=N), 1439 (thiazole) cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 4.82 (s, 2H, NH₂, disappeared on D₂O exchange), 8.94 (s, 1H, NH, disappeared on D₂O exchange), 2.45 (s, 3H, CH₃), 7.26–7.71 (m, 3H, 3CH) ppm. Anal. calcd. for C₈H₉N₃S: C, 53.61; H, 5.06; N, 23.44; Found: C, 53.57; H, 5.08; N, 23.47%.

(2e). Yield 65%; m.p. 193–195°C; IR (KBr): 3439 (NH₂), 3208 (NH), 1628 (C=N), 1448 (thiazole) cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 4.80 (s, 2H, NH₂, disappeared on D₂O exchange), 8.94 (s, 1H, NH, disappeared on D₂O exchange), 3.86 (s, 1H, OCH₃), 7.16–7.65 (m, 3H, 3CH) ppm. Anal. calcd. for $C_8H_9N_3OS$: C, 49.21; H, 4.65; N, 21.52; Found: C, 49.25; H, 4.62; N, 21.48%.

(2f). Yield 68%; m.p. 198–200°C; IR (KBr): 3445 (NH₂), 3218 (NH), 1624 (C=N), 1428 (thiazole) cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 4.79 (s, 2H, NH₂, disappeared on D₂O exchange), 8.90 (s, 1H, NH, disappeared on D₂O exchange), 7.82–8.21 (m, 3H, 3CH) ppm. Anal. calcd. for C₇H₆N₃ClS: C, 42.11; H, 3.03; N, 17.76; Found: C, 42.15; H, 3.07; N, 17.79%.

(2g) Yield 69%; m.p. 167–169°C; IR (KBr): 3439 (NH₂), 3220 (NH), 1638 (C=N), 1435 (thiazole) cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 4.83 (s, 2H, NH₂, disappeared on D₂O exchange), 8.92 (s, 1H, NH, disappeared on D₂O exchange), 2.83 (s, 3H, CH₃), 7.31–7.69 (m, 3H, 3CH) ppm. Anal. calcd. for C₈H₉N₃S: C, 53.61; H, 5.06; N, 23.44; Found: C, 53.65; H, 5.01; N, 23.38%.

(2h). Yield 60%; m.p. 199–201°C; IR (KBr): 3440 (NH₂), 3200 (NH), 1631 (C=N), 1445 (thiazole) cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 4.88 (s, 2H, NH₂, disappeared on D₂O exchange), 8.95 (s, 1H, NH, disappeared on D₂O exchange), 7.06–8.82 (m, 3H, 3CH) ppm. Anal. calcd. for C₇H₆N₄O₂S: C, 40.00; H, 2.88; N, 26.65; Found: C, 40.04; H, 2.85; N, 26.61%.

(2i). Yield 68%; m.p. 248–250°C; IR (KBr): 3449 (NH₂), 3212 (NH), 1640 (C=N), 1439 (thiazole) cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 4.86 (s, 2H, NH₂, disappeared on D₂O exchange), 8.94 (s, 1H, NH, disappeared on D₂O exchange), 7.81 (s, 1H, CH), 7.98 (s, 1H, CH) ppm. Anal. calcd. for C₇H₅N₃Cl₂S: C, 35.91; H, 2.15; N, 17.95; Found: C, 35.88; H, 2.19; N, 17.92%.

(2j). Yield 63%; m.p. 239–241°C; IR (KBr): 3449 (NH₂), 3220 (NH), 1640 (C=N), 1445 (thiazole) cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 4.82 (s, 2H, NH₂, disappeared on D₂O exchange), 8.92 (s, 1H, NH, disappeared on D₂O exchange), 7.55–7.87 (m, 3H, 3CH) ppm. Anal. calcd. for C₇H₆N₃ClS: C, 42.11; H, 3.03; N, 17.76; Found: C, 42.07; H, 3.01; N, 18.00%.

2-(3-Pyridyl)-5-(4-nitrophenyl)-1,3,4-oxadiazole (5)

A mixture of nicotinoyl hydrazide (4) (5 mmol) and 4-nitro benzoic acid (5 mmol) in phosphorus oxychloride (5 mL) was refluxed on water bath for 9 h. The progress of the reaction was monitored by TLC using toluene:ethylacetate:methanol (70:20:10) as mobile phase. After the completion of reaction, it was cooled and poured onto crushed ice with continuous stirring. The solid mass separated was neutralized with sodium bicarbonate solution (10% w/v). The resulting solid thus obtained was collected by filtration, washed well with cold water, dried, and crystallized from absolute ethanol.

(5). Yield 65%; m.p. 121–123°C; IR (KBr): 1667 (C=N), 1284, 1078 (C-O-C) cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 9.38 (s, 1H, CH), 8.83 (dd, 1H, *J*=3.48 Hz, CH), 8.39–8.48 (m, 5H, 5CH), 7.61 (t, 1H, CH) ppm; ¹³C NMR (400 MHz, CDCl₃) δ 160.22 (C₂-oxadiazole), 159.58 (C₅-oxadiazole), 149.50, 146.88, 145.38, 135.83, 129.65, 128.68, 124.68, 124.29, 123.34 (aromatic ring) ppm; MS (*m*/*z*): 268 (M⁺);

Anal. calcd. for C₁₃H₈N₄O₃: C, 58.21; H, 3.01; N, 20.89; Found: C, 58.17; H, 3.04; N, 20.85%.

General procedure for the synthesis of 3-(3-pyridyl)-5-(4-nitrophenyl)-4-(*N*-substituted-1,3-benzothiazol-2amino)-4*H*-1,2,4-triazole (**6a**–**j**)

A mixture of 2-(3-pyridyl)-5-(4-nitrophenyl)-1,3,4-oxadiazole (**5**) (5 mmol) and substituted 2-hydrazino-1,3benzothiazole (**2a-j**) (5 mmol) in dry pyridine (10 mL) was refluxed for 18–24 h. The reaction was monitored by TLC on silica gel using ethyl acetate:toluene (2.5:7.5). It was then cooled and poured on to crushed ice. The reaction mass was neutralized by dilute hydrochloric acid and resulting solid was washed with cold water, dried, and crystallized from absolute ethanol. The other compounds of the series were prepared by similar procedure (Scheme 1).

(6a). Yield 66%; m.p. 210–212°C; IR (KBr): 3434 (NH), 1649 (C=N) cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.73 (s, 1H, NH), 9.38 (s, 1H, CH), 8.84 (dd, 1H, *J*=4.0 Hz, CH), 8.39–8.49 (m, 5H, 5CH), 7.60 (t, 1H, CH), 7.06–7.26 (m, 3H, benzothiazole-H); ¹³C NMR (400 MHz, CDCl₃) δ 163.48 (C₃-triazole), 163.35 (C₅-triazole), 152.91, 149.66, 147.94, 145.66, 138.43, 134.42, 132.66, 131.12, 129.03, 129.12, 128.15, 124.55, 124.19, 121.91, 113.66, 109.85 (aromatic ring) ppm; MS (*m*/*z*): 433 (M⁺); Anal. calcd. for C₂₀H₁₂N₇O₂FS: C, 55.42; H, 2.79; N, 22.62; Found: C, 55.38; H, 2.81; N, 22.71%.

(**6b**). Yield 62%; m.p. 199–201°C; IR (KBr): 3432 (NH), 1646 (C=N) cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.79 (s,



i. NH₄SCN,Br₂, Glacial acetic acid, NH₃; ii. Hydrazine Hydrate, conc. HCl, Ethylene Glycol;
iii. NH₂NH₂.H₂O, ethanol, refluxed; iv. POCl₃, reflux 9h;
v. dry pyridine, refluxed

R = a. 6-F,	d. 6-CH ₃ ,	g. 4-CH ₃ ,	j. 4-Cl
b. 6-Br,	e. 6-OCH ₃ ,	h. 4-NO ₂ ,	
c. 6-NO ₂ ,	f. 6-Cl,	i. 5-Cl,6-Cl,	

Scheme 1. Synthetic protocol for the compounds 6a-j.

1H, NH), 9.37 (s, 1H, CH), 8.82 (dd, 1H, *J*=4.0 Hz, CH), 8.40–8.51 (m, 5H, 5CH), 7.56 (t, 1H, CH), 7.61-7.76 (m, 3H, benzothiazole-H); ¹³C NMR (400 MHz, CDCl₃) δ 163.28 (C₃-triazole), 162.69 (C₅-triazole), 153.03, 149.82, 147.69, 145.60, 136.69, 134.28, 133.15, 131.43, 129.03, 128.15, 127.78, 124.49, 124.16, 123.09, 118.99, 111.63 (aromatic ring) ppm; MS (*m*/*z*): 494 (M⁺), 496 (M+2); Anal. calcd. for C₂₀H₁₂N₇O₂BrS: C, 48.59; H, 2.45; N, 19.83; Found: C, 48.63; H, 2.41; N, 19.79%.

(6c). Yield 69%; m.p. 186–188°C; IR (KBr): 3449 (NH), 1652 (C=N) cm⁻¹; ¹H NMR (400 MHz, CDCl₃) 7.80 (s, 1H, NH), 9.38 (s, 1H, CH), 8.83 (dd, 1H, *J*=3.8 Hz, CH), 8.36–8.47 (m, 5H, 5CH), 7.62 (t, 1H, CH), 7.33 (d, 1H, *J*=8.16 Hz, CH), 7.56 (d, 1H, *J*=7.85 Hz, CH), 8.74 (s, 1H, CH); ¹³C NMR (400 MHz, CDCl₃) δ 162.94 (C₃-triazole), 162.53 (C₅-triazole), 152.96, 148.83, 147.74, 146.61, 141.77, 134.48, 132.86, 132.32, 129.03, 129.53, 129.31, 124.61, 124.19, 121.98, 110.58, 119.72 (aromatic ring) ppm; MS (*m/z*): 460 (M⁺); Anal. calcd. for C₂₀H₁₂N₈O₄S: C, 52.17; H, 2.63; N, 24.34; Found: C, 52.21; H, 2.59; N, 24.31%.

(6d). Yield 70%; m.p. 179–180°C; IR (KBr): 3447 (NH), 1661 (C=N) cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 2.34 (s, 3H, CH₃), 7.82 (s, 1H, NH), 9.37 (s, 1H, CH), 8.82 (dd, 1H, *J*=4.0 Hz, CH), 8.39–8.52 (m, 5H, 5CH), 7.56 (t, 1H, CH), 7.05-7.50 (m, 3H, benzothiazole-H); ¹³C NMR (400 MHz, CDCl₃) δ 163.07 (C₃-triazole), 162.61 (C₅-triazole), 22.91 (CH₃), 152.93, 149.57, 148.01, 144.75, 135.28, 135.07, 131.31, 129.05, 129.92, 128.79, 128.52, 124.61, 124.21, 124.02, 121.27, 121.38 (aromatic ring) ppm; MS (*m*/*z*): 429 (M⁺); Anal. calcd. for C₂₁H₁₅N₇O₂S: C, 58.73; H, 3.52; N, 22.83; Found: C, 58.77; H, 3.47; N, 22.78%.

(**6e**). Yield 71%; m.p. 189–191°C; IR (KBr): 3449 (NH), 1655 (C=N) cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 3.82 (s, 3H, OCH₃), 7.76 (s, 1H, NH), 9.36 (s, 1H, CH), 8.81 (dd, 1H, *J*=4.0 Hz, CH), 8.39–8.48 (m, 5H, 5CH), 7.59 (t, 1H, CH), 6.84–7.28 (m, 3H, benzothiazole-H); ¹³C NMR (400 MHz, CDCl₃) δ 163.38 (C₃-triazole), 162.82 (C₅-triazole), 52.59 (OCH₃), 152.91, 149.99, 147.76, 147.35, 143.02, 134.36, 132.60, 132.44, 131.13, 129.13, 128.42, 124.23, 124.08, 119.15, 113.98, 106.25 (aromatic ring) ppm; MS (*m*/*z*): 445 (M⁺); Anal. calcd. for C₂₁H₁₅N₇O₃S: C, 56.62; H, 3.39; N, 22.01; Found: C, 56.66; H, 3.41; N, 21.98%.

(**6f**). Yield 65%; m.p. 204–206°C; IR (KBr): 3442 (NH), 1657 (C=N) cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.80 (s, 1H, NH), 9.36 (s, 1H, CH), 8.82 (dd, 1H, *J*=3.8 Hz, CH), 8.37–8.48 (m, 5H, 5CH), 7.52 (t, 1H, CH), 7.59–7.76 (m, 3H, benzothiazole-H); ¹³C NMR (400 MHz, CDCl₃) δ 163.34 (C₃-triazole), 162.85 (C₅-triazole), 152.87, 148.97, 147.32, 144.44, 134.08, 131.52, 131.05, 129.09, 127.81, 127.62, 126.85, 125.47, 124.33, 123.84, 121.95, 121.52 (aromatic ring) ppm; MS (*m*/*z*): 449 (M⁺), 451 (M+2); Anal. calcd. for C₂₀H₁₂N₇O₂ClS: C, 53.40; H, 2.69; N, 21.79; Found: C, 53.42; H, 2.73; N, 21.83%.

(**6g**). Yield 65%; m.p. 192–194°C; IR (KBr): 3435 (NH), 1660 (C=N) cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 2.61 (s, 3H, CH₃), 7.76 (s, 1H, NH), 9.36 (s, 1H, CH), 8.82 (dd, 1H, *J*=3.8 Hz, CH), 8.38–8.49 (m, 5H, 5CH), 7.59 (t, 1H, CH), 7.09–7.28 (m, 3H, benzothiazole-H); ¹³C NMR (400 MHz, $\begin{array}{l} {\rm CDCl}_3 \ \delta \ 163.18 \ ({\rm C}_3\mbox{-triazole}), \ 162.65 \ ({\rm C}_5\mbox{-triazole}), \ 20.82 \ ({\rm CH}_3), \ 152.88, \ 148.93, \ 146.98, \ 143.47, \ 134.28, \ 132.47, \ 132.25, \ 131.07, \ 129.18, \ 128.96, \ 128.82, \ 127.57, \ 124.53, \ 123.98, \ 122.04, \ 120.96 \ (aromatic \ ring) \ ppm; \ MS \ (m/z): \ 429 \ ({\rm M}^+); \ Anal. \ calcd. \ for \ {\rm C}_{21}{\rm H}_{15}{\rm N}_7{\rm O}_2{\rm S}: \ {\rm C}, \ 58.73; \ {\rm H}, \ 3.52; \ {\rm N}, \ 22.83; \ {\rm Found: C, \ 58.81; \ H, \ 3.57; \ N, \ 22.87\%. \end{array}$

(**6h**). Yield 67%; m.p. 171–173°C; IR (KBr): 3442 (NH), 1659 (C=N) cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.75 (s, 1H, NH), 9.37 (s, 1H, CH), 8.82 (dd, 1H, *J*=4.0 Hz, CH), 8.39–8.48 (m, 5H, 5CH), 7.60 (t, 1H, CH), 8.22 (d, 1H, *J*=8.16 Hz, CH), 8.56 (d, 1H, *J*=8.14 Hz, CH), 6.63 (t, 1H, CH); ¹³C NMR (400 MHz, CDCl₃) δ 162.94 (C₃-triazole), 162.45 (C₅-triazole), 152.21, 148.83, 147.74, 144.36, 138.06, 134.67, 132.10, 131.98, 131.81, 129.23, 128.07, 127.60, 124.20, 123.91, 122.55, 120.65 (aromatic ring) ppm; MS (*m/z*): 460 (M⁺); Anal. calcd. for C₂₀H₁₂N₈O₄S: C, 52.17; H, 2.63; N, 24.34; Found: C, 52.21; H, 2.67; N, 24.37%.

(6i). Yield 68%; m.p. 205–207°C; IR (KBr): 3449 (NH), 1649 (C=N) cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.88 (s, 1H, NH), 9.36 (s, 1H, CH), 8.81 (dd, 1H, *J*=3.8 Hz, CH), 8.38–8.50 (m, 5H, 5CH), 7.59 (t, 1H, CH), 7.59 (s, 1H, CH), 7.66 (s, 1H, CH); ¹³C NMR (400 MHz, CDCl₃) δ 163.34 (C₃-triazole), 162.89 (C₅-triazole), 152.35, 149.74, 147.82, 144.86, 134.29, 133.72, 133.50, 129.69, 129.41, 128.02, 128.75, 124.46, 124.02, 123.37, 123.78, 121.74 (aromatic ring) ppm; MS (*m*/*z*): 484 (M⁺), 486 (M+2), 488 (M+4); Anal. calcd. for C₂₀H₁₁N₇O₂Cl₂S: C, 49.60; H, 2.29; N, 20.24; Found: C, 49.64; H, 2.26; N, 20.21%.

(6j). Yield 65%; m.p. 191–193°C; IR (KBr): 3438 (NH), 1661 (C=N) cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.76 (s, 1H, NH), 9.37 (s, 1H, CH), 8.81 (dd, 1H, *J*=4.0 Hz, CH), 8.38–8.51 (m, 5H, 5CH), 7.61 (t, 1H, CH), 6.91–7.30 (m, 3H, benzothiazole-H); ¹³C NMR (400 MHz, CDCl₃) δ 163.42 (C₃-triazole), 162.96 (C₅-triazole), 152.59, 148.96, 146.89, 144.86, 134.12, 131.65, 131.32, 131.59, 128.02, 127.81, 124.47, 124.08, 123.18, 120.29, 120.18, 118.79 (aromatic ring) ppm; MS (*m*/*z*): 449 (M⁺), 451 (M+2); Anal. calcd. for C₂₀H₁₂N₇O₂CIS: C, 53.40; H, 2.69; N, 21.79; Found: C, 53.34; H, 2.72; N, 21.83%.

Antimicrobial activity

The minimum inhibitory concentrations (MICs) of synthesized compounds were carried out by broth microdilution method as described by Rattan.²⁵ Antibacterial activity was screened against two Gram-positive bacteria (*Staphylococcus aureus* MTCC 96 and *Streptococcus pyogenes* MTCC 442) and two Gram-negative bacteria (*Escherichia coli* MTCC 443 and *Pseudomonas aeruginosa* MTCC 2488). Ampicillin was used as a standard antibacterial agent. Antifungal activity was screened against three fungal species *Candida albicans* MTCC 227, *Aspergillus niger* MTCC 282, and *Aspergillus clavatus* MTCC 1323. Griseofulvin was used as a standard antifungal agent.

All MTCC cultures were collected from Institute of Microbial Technology, Chandigarh and tested against above mentioned known drugs. Mueller hinton broth was used as nutrient medium to grow and dilute the drug suspension for the test. Inoculum size for test strain was adjusted to 10⁸ colony-forming unit (CFU) per millilitre by comparing the turbidity. Dimethyl sulphoxide (DMSO) was used as diluents to get desired concentration of drugs to test upon standard bacterial strains. Serial dilutions were prepared in primary and secondary screening. The control tube containing no antibiotic was immediately subcultured (before inoculation) by spreading a loopful evenly over a quarter of plate of medium suitable for the growth of the test organism and put for incubation at 37°C overnight. The tubes were then incubated overnight. The MIC of the control organism was read to check the accuracy of the drug concentrations. The lowest concentration inhibiting growth of the organism was recorded as the MIC. All the tubes not showing visible growth (in the same manner as control tube described earlier) was subcultured and incubated overnight at 37°C. The amount of growth from the control tube before incubation (which represents the original inoculum) was compared. Subcultures might show similar number of colonies indicating bacteriostatic, a reduced number of colonies indicating a partial or slow bactericidal activity and no growth if the whole inoculum has been killed. The test must include a second set of the same dilutions inoculated with an organism of known sensitivity. Each synthesized drug was diluted obtaining 2000 µg/mL concentration, as a stock solution. In primary screening, 500, 250, and 125 μ g/mL concentrations of the synthesized drugs were taken. The active synthesized compounds found in this primary screening were further tested in a second set of dilution against all microorganisms. The drugs found active in primary screening were similarly diluted to obtain 100, 50, 25, 12.5, 6.250, 3.125, and 1.5625 μ g/mL concentrations. The highest dilution showing at least 99% inhibition is taken as MIC.

Antitubercular activity

Drug susceptibility and determination of MIC of the test compounds against M. tuberculosis H₃₇Rv were performed by L.J. agar (MIC) method²⁵⁻²⁸ where primary 1000, 500, 250 and secondary 200, 100, 62.5, 50, 25, 12.5, 6.25, 3.25 μ g/mL dilutions of each test compound were added; liquid L.J. medium and then media were sterilized by inspissation method. A culture of M. tuberculosis H₃₇Rv growing on L.J. medium was harvested in 0.85% saline in bijou bottles. All test compounds that make first stock solution of 2000 µg/mL concentration of compounds were prepared in DMSO. These tubes were then incubated at 37°C for 24h followed by streaking of *M. tuberculosis* H_{37} Rv (5×10⁴ bacilli per tube). These tubes were then incubated at 37°C. Growth of bacilli was seen after 12 days, 22 days, and finally 28 days of incubation. Tubes having the compounds were compared with control tubes where medium alone was incubated with *M. tuberculosis* H_{37} Rv. The concentration at which no development of colonies occurred or <20 colonies was taken as MIC concentration of test compound. The standard strain M. tuberculosis H₃₇Rv was tested with known drug rifampicin.

Results and discussion

Chemistry

2-Amino-6-flouro-1,3-benzothiazole 1a on treatment of hydrazine hydrate, concentrated hydrochloric acid, and ethylene glycol yields 2-hydrazino-6-flouro-1,3benzothiazole 2a. IR spectra of 2a showed broad stretching band around 3425 and 3200 cm⁻¹ for NH and NH₂. ¹H NMR spectrum showed a singlet at δ 4.83 and δ 8.93, which were accounted for NH₂ and NH, which vanished on $D_{2}O$ exchange. Ethyl nicotinate **3** on treatment with hydrazine hydrate yields nicotinoyl hydrazide 4; the IR spectra of 4 showed stretching band around 3335 and 3278 cm⁻¹ due to amine/amide NH, whereas strong stretching band at 1610 cm⁻¹ was attributed to amide carbonyl. ¹H NMR spectrum showed a singlet at δ 4.51 and δ 9.81, which were accounted for NH₂ and NH, which vanished on D₂O exchange. Intermolecular cyclization of nicotinoyl hydrazide 4 with 4-nitrobenzoic acid in presence of phosphorus oxy chloride affords 2-(3-pyridyl)-5-(4-nitrophenyl)-1,3,4-oxadiazole 5. Disappearance of ¹H NMR resonances observed with NH and NH₂ functions in the ¹H NMR spectrum of 5 proved that ring closure starting from 4 resulted in the formation of 1,3,4-oxadiazole ring. This was further substantiated by the 13C NMR data of 5, which showed a peak at δ 160.22 and δ 159.58 due to C₂ and C₅ of oxadiazole. Mass spectrum of **5** displayed a molecular ion peak at m/z 268 that confirmed its molecular weight. Condensation of 5 with various substituted 2-hydrazino-1,3-benzothiazole 2a-j in pyridine results in 3-(3-pyridyl)-5-(4-nitrophenyl)-4-(N-substituted-1,3benzothiazol-2-amino)-4H-1,2,4-triazole 6a-j. Absence of ¹H NMR resonances observed with NH₂ function of **2a** and appearance of signal at δ 7.73 for NH was observed in ¹H NMR of **6a** proved the condensation of **2** and **5** resulted in the formation of 1,2,4-triazole ring. This was substantiated by ¹³C NMR data of **6a** that showed a peak at δ 163.48 and δ 163.35 due to C₃ and C₅ of triazole. Mass spectrum of **6** displayed a molecular ion at m/z 433 that confirmed its molecular weight.

Antibacterial activity

The MICs of the tested compounds are shown in Tables 1 and 2. The results revealed that substituted 2-hydrazino benzothiazoles were moderately active against bacteria except 2e, which showed good activity against S. aureus and E. coli while 1,3,4-oxadiazole 5 exhibited quite good activity to some extent. Most of 1,2,4-triazole derivative were found good activity (62.5-250 µg/mL) against S. aureus. Compounds 6b, 6c, 6f, 6g, and 6j exhibited pronounced activity (62.5-125 µg/mL) against S. aureus. All the compounds exhibited moderate activity (150-250 μ g/mL) except **6b** and **6j** (62.5 μ g/mL) against S. pyogenes. Compounds 6b, 6f, 6g, 6h, and 6j possessed good activity (100-125 µg/mL) except 6c showed pronounced activity (62.5 µg/mL) while others displayed moderate activity (150-250 µg/mL) against E. coli. Compounds 6c and 6d showed good activity (100 µg/mL) except 6i showed very good activity ($62.5 \ \mu g/mL$) while others possessed moderate activity ($150-250 \ \mu g/mL$) against *P. aeruginosa*. Compounds **6b**, **6c**, **6f**, **6g**, and **6j** exhibited good activity against Gram-positive bacteria, whereas

6c, **6g**, **6i**, and **6j** showed good activity toward Gramnegative bacteria. Compounds **2e**, **6c**, **6g**, and **6j** were found active against Gram-positive and Gram-negative bacteria.

Table 1	Minimum	inhihitory	concentrations	(MICs u	σ/mL	for the t	itle com	nounds
Table 1.	winninum	minutory	concentrations	(μπος, μ	ig/mLJ	ior me i	ine com	pounus.

		Gram-posi	tive bacteria	Gram-negative	bacteria
		S. aureus	S. pyogenes	E. coli	P. aeruginosa
Compound	R	MTCC 96	MTCC 442	MTCC 443	MTCC 2488
2a	6-F	500	250	250	250
2b	6-Br	250	500	500	500
2c	$6-NO_2$	500	500	250	250
2d	6-CH ₃	250	250	100	500
2e	6-OCH ₃	200	250	62.5	125
2f	6-Cl	500	500	100	125
2g	$4-CH_3$	500	500	250	250
2h	$4-NO_2$	500	250	500	250
2i	5-Cl, 6-Cl	250	500	100	125
2j	4-Cl	500	500	250	250
5	—	100	125	500	250
6a	6-F	250	250	250	500
6b	6-Br	100	62.5	125	250
6c	$6-NO_2$	62.5	500	62.5	100
6d	6-CH ₃	250	250	150	100
6e	6-OCH ₃	250	125	500	250
6f	6-Cl	125	500	125	250
6g	$4-CH_3$	100	1000	100	250
6h	$4-NO_2$	500	250	125	200
6i	5-Cl, 6-Cl	1000	250	500	62.5
6j	4-Cl	100	62.5	100	250
Ampicillin	_	250	100	100	100

Table 2. Minimum inhibitory concentrations (MICs, μ M) for the title compounds.

		Gram-posi	Gram-positive bacteria		Gram-negative bacteria	
		S. aureus	S. pyogenes	E. coli	P. aeruginosa	
Compound	R	MTCC 96	MTCC 442	MTCC 443	MTCC 2488	
2a	6-F	2732	1366	1366	1366	
2b	6-Br	1024	2049	2049	2049	
2c	$6-NO_2$	2380	2380	1190	1190	
2d	$6-CH_3$	1396	1396	558.6	2793	
2e	6-OCH ₃	1025	1282	320.5	641.0	
2f	6-Cl	2512	2512	502.5	628.1	
2g	$4-CH_3$	2793	2793	1396	1396	
2h	$4-NO_2$	2380	1190	2380	1190	
2i	5-Cl, 6-Cl	1068	2136	427.3	534.2	
2j	4-Cl	2512	2512	1256	1256	
5	—	373.1	466.4	1865	932.8	
6a	6-F	577.3	577.3	577.3	1154	
6b	6-Br	202.4	126.5	253.0	506.0	
6c	$6-NO_2$	135.8	1086	135.8	217.4	
6d	6-CH ₃	582.7	582.7	349.6	233.1	
6e	6-OCH ₃	561.8	280.9	1123	561.8	
6f	6-Cl	278.4	1113	278.4	556.6	
6g	$4-CH_3$	233.1	2331	233.1	582.7	
6h	$4-NO_2$	1086	543.4	271.7	434.7	
6i	5-Cl, 6-Cl	2066	516.5	1033	124.1	
6j	4-Cl	222.7	139.2	222.7	556.8	
Ampicillin	_	716.3	286.5	286.5	286.5	

Antifungal activity

In vitro antifungal activities (MICs) of the synthesized compounds are shown in Tables 3 and 4. The results showed that 2-hydrazino benzothiazoles 2a-i possessed good activity (250-500 µg/mL) against C. albicans except 2j (1000 µg/mL). Compounds 2a-j displayed moderate to weak activity (250-500 µg/mL) against A. niger and A. clavatus, whereas 1,3,4-oxadiazole 5 exhibited weak activity against all three fungi. Compounds 6c, 6d, 6e, **6f**, **6i**, and **6j** showed good activity (250–500 μ g/mL), whereas 6a and 6h exhibited pronounced activity (100 µg/mL) against *C. albicans*. Compounds **6a**, **6h**, and **6i** exhibited moderate activity (200-250 µg/ml), whereas remaining compounds showed weak activity against A. niger. Compounds 6d and 6h displayed moderate activity (200-250 μ g/mL), whereas rest of the compounds showed weak activity against A. clavatus. Compounds 2f, 2g, 2h, 6a, 6d, and 6h were found active against all the three fungal species.

Antitubercular activity

The encouraging results from the antibacterial studies impelled us to go for preliminary screening of synthesized compounds against *M. tuberculosis* are summarized in Table 5. From the preliminary examination of the antitubercular activity results, compound **2e** containing hydrazide group showed better activity (50 μ g/mL) against *M. tuberculosis* and compounds **6a**, **6e**, and **6j** showed good activity (50–62.5 μ g/mL). Due to the better activity against tested microorganisms and mycobacteria, compound **6j**

Table 3. Minimum inhibitory concentrations (MICs, $\mu g/mL)$ for the title compounds.

		F	ungal species	
	-	C. albicans	A. niger	A. clavatus
Compound	R	MTCC 227	MTCC 282	MTCC 323
2a	6-F	250	1000	1000
2b	6-Br	500	500	500
2c	$6-NO_2$	500	500	1000
2d	$6-CH_3$	250	500	1000
2e	6-OCH ₃	500	500	250
2f	6-Cl	250	200	250
2g	$4-CH_3$	500	250	200
2h	$4-NO_2$	200	250	200
2i	5-Cl, 6-Cl	500	500	1000
2j	4-Cl	1000	500	500
5	—	>1000	>1000	>1000
6a	6-F	100	250	1000
6b	6-Br	>1000	>1000	>1000
6c	$6-NO_2$	500	500	1000
6d	$6-CH_3$	250	500	250
6e	6-OCH ₃	250	500	1000
6f	6-Cl	500	1000	1000
6g	$4-CH_3$	>1000	>1000	>1000
6h	$4-NO_2$	100	200	200
6i	5-Cl, 6-Cl	500	250	500
6j	4-Cl	500	>1000	>1000
Griseofulvin	_	500	100	100

has been selected for further development, and studies to acquire more information about structure-activity relationships are in progress in our laboratories.

Table 4. Minimum inhibitory concentrations (MICs, μM) for the title compounds.

		Fungal species				
		C. albicans	A. niger	A. clavatus		
Compound	R	MTCC 227	MTCC 282	MTCC 323		
2a	6-F	1366	5464	5464		
2b	6-Br	2049	2049	2049		
2c	$6-NO_2$	2380	2380	4761		
2d	$6-CH_3$	1396	2793	5586		
2e	6-OCH ₃	2564	2564	1282		
2f	6-Cl	1265	1005	1265		
2g	$4-CH_3$	2793	1396	1117		
2h	$4-NO_2$	952.3	1190	952.3		
2i	5-Cl, 6-Cl	2136	2136	4273		
2j	4-Cl	5025	2512	2512		
5	_	>2731	>2731	>2731		
6a	6-F	230.9	577.3	2309		
6b	6-Br	>2024	>2024	>2024		
6c	$6-NO_2$	1086	1086	2173		
6d	6-CH ₃	582.7	1165	582.7		
6e	6-OCH ₃	561.8	1123	2247		
6f	6-Cl	1113	2227	2227		
6g	4-CH ₃	>2331	>2331	>2331		
6h	$4 - NO_2$	217.4	434.8	434.8		
6i	5-Cl, 6-Cl	1033	0516	1033		
6j	4-Cl	1113	>2227	>2227		
Griseofulvin		1420	284.0	284.0		

Table	5.	Minimum in	nhibitory concentra	tions (MICs,	$\mu g/mL$ and
μM) f	or	the title com	pounds.		

		MIC val tubercule		
Compound	R	μg/mL	μΜ	% Inhibition
2a	6-F	250	1366	98%
2b	6-Br	500	2049	96%
2c	$6-NO_2$	250	1109	98%
2d	6-CH ₃	1000	5586	95%
2e	6-OCH ₃	50	256.4	98%
2f	6-Cl	200	1005	96%
2g	$4-CH_3$	500	2793	95%
2h	$4-NO_2$	500	2380	97%
2i	5-Cl, 6-Cl	250	1068	98%
2j	4-Cl	100	502.5	96%
5	—	1000	3731	95%
6a	6-F	200	461.6	96%
6b	6-Br	62.5	126.5	98%
6c	$6-NO_2$	250	543.4	96%
6d	6-CH ₃	100	233.1	98%
6e	6-OCH ₃	62.5	140.44	96%
6f	6-Cl	250	556.8	94%
6g	$4-CH_3$	1000	2331	97%
6h	$4-NO_2$	100	217.4	96%
6i	5-Cl, 6-Cl	200	413.2	98%
6j	4-Cl	50	111.3	98%
Rifampicin	_	40	48.66	98%

Conclusion

A series of newer analogues 1,2,4-triazoles were synthesized by the introduction of 2-hydrazino benzothiazoles to 1,3,4-oxadiazoles and accessed for antimicrobial and antitubercular activity. Modification of substituents on benzothiazoles ring with various electron-releasing and electron-withdrawing substituents improved the activity. The analogues with halogen, methyl, and nitro substituents emerged as promising antibacterials showing better to moderate activity, whereas analogues bearing nitro substituent showed better antifungal activity. It was also observed that the promising antimicrobials have proved to be better antituberculars. Specially, compound **6j** due to their better activity against H_{37} Rv strain, is the best choice for the preparation of new derivatives in order to improve antitubercular activity in future.

Acknowledgements

The authors are thankful to Veer Narmad South Gujarat University for providing necessary facilities and research fellowship. We also thank SAIF Lucknow for elemental analysis and SAIF Chandigarh for spectral analysis of the compounds and D. Rajani, Microbial Laboratory, Surat, for antimicrobial and antimycobacterial activity.

Declaration of interest

The authors report no conflict of interest. The authors alone are responsible for the content and writing of the article.

References

- 1. Stokstad, E. Infectious disease. Drug-resistant TB on the rise. Science 2000, 287, 2391.
- WHO Global Tuberculosis Programme—Tuberculosis Fact Sheet, 2002. World Health Organization. Global Tuberculosis Control, WHO Report 2001, 2002.
- World Health Organization, Geneva, Switzerland, WHO/CDS/ TB/2001, 287. http://www.who.int/mediacentre/factsheets/ who104/en/index.html
- Mooran, N. WHO issues another gloomy tuberculosis report. Nat. Med. 1996, 2, 377.
- Dye, C., Scheele, S., Dolin, P., Pathania, V., Raviglione, M.C. Global burden of tuberculosis: estimated incidence, prevalence and mortality by country. J. Am. Med. Assoc. 1999, 282, 677-686.
- Dooley, S.W., Jarvis, W.R., Martone, W.J., Snider, D.E. Jr. Multidrugresistant tuberculosis. Ann. Intern. Med. 1992, 117, 257–259.
- Raviglione, M.C., Snider, D.E. Jr, Kochi, A. Global epidemiology of tuberculosis. Morbidity and mortality of a worldwide epidemic. JAMA 1995, 273, 220–226.
- Farmer, P., Bayona, J., Becerra, M., Furin, J., Henry, C., Hiatt, H., Kim, J.Y., Mitnick, C., Nardell, E., Shin, S. The dilemma of MDR-TB in the global era. Int. J. Tuberc. Lung Dis. 1998, 2, 869–876.
- 9. Hudson, A., Imamura, T., Gutteridge, W., Kanyok, T., Nunn, P. The Current Anti-TB Drug Research and Development Pipeline. WHO TDR/PRD/03.1W Geneva, 2003.
- Tripathi, R.P., Tewari, N., Dwivedi, N., Tiwari, V.K. Fighting tuberculosis: an old disease with new challenges. Med. Res. Rev. 2005, 25, 93–131.

- 11. Banfi, E., Scialino, G., Zampieri, D., Mamolo, M.G., Vio, L., Ferrone, M., Fermeglia, M., Paneni, M.S., Pricl, S. Antifungal and antimycobacterial activity of new imidazole and triazole derivatives. A combined experimental and computational approach. J. Antimicrob. Chemother. 2006, 58, 76-84.
- Ulusoy, N., Gürsoy, A., Otük, G. Synthesis and antimicrobial activity of some 1,2,4-triazole-3-mercaptoacetic acid derivatives. Farmaco 2001, 56, 947–952.
- Muhi-Eldeen Z, Nadir M, Aljobory NR, Husseen F, Stohs SJ. Synthesis and antimicrobial evaluation of 3-(4-tert-amino-2butynyl)thio and alkyl/alkenylthio-4,5-disubstituted-4H-1,2,4triazoles. Eur. J. Med. Chem. 1991, 26, 237-241.
- 14. Küçükgüzel, I., Tatar, E., Küçükgüzel, S.G., Rollas, S., De Clercq, E. Synthesis of some novel thiourea derivatives obtained from 5-[(4-aminophenoxy)methyl]-4-alkyl/aryl-2,4-dihydro-3H-1,2,4-triazole-3-thiones and evaluation as antiviral/anti-HIV and anti-tuberculosis agents. Eur. J. Med. Chem. 2008, 43, 381-392.
- Banfi, E., Mamolo, M.G., Zampieri, D., Vio, L., Monti Bragadin, C. Antimycobacterial activity of *N*1-[1-[3-aryl-1-(pyridin-2-, 3- or 4-yl)-3-oxo] propyl]-2-pyridinecarboxamidrazones. J. Antimicrob. Chemother. 2001, 48, 705–707.
- Jackson, C.J., Lamb, D.C., Kelly, D.E., Kelly, S.L. Bactericidal and inhibitory effects of azole antifungal compounds on *Mycobacterium smegmatis*. FEMS Microbiol. Lett. 2000, 192, 159–162.
- 17. Guardiola-Diaz, H.M., Foster, L.A., Mushrush, D., Vaz, A.D. Azoleantifungal binding to a novel cytochrome P450 from *Mycobacterium tuberculosis*: implications for treatment of tuberculosis. Biochem. Pharmacol. 2001, 61, 1463–1470.
- McLean, K.J., Marshall, K.R., Richmond, A., Hunter, I.S., Fowler, K., Kieser, T., Gurcha, S.S., Besra, G.S., Munro, A.W. Azole antifungals are potent inhibitors of cytochrome P450 mono-oxygenases and bacterial growth in mycobacteria and streptomycetes. Microbiology 2002, 30, 314–318.
- Dabiri, M., Salehi, P., Baghbanzadeh, M., Bahramnejad, M. A facile procedure for the one-pot synthesis of unsymmetrical 2,5-disubstituted 1,3,4-oxadiazoles. Tetrahedron Lett. 2006, 47, 6983–6986.
- Navarrete-Vázquez, G., Molina-Salinas, G.M., Duarte-Fajardo, Z.V., Vargas-Villarreal, J., Estrada-Soto, S., González-Salazar, F., Hernández-Núñez, E., Said-Fernández, S. Synthesis and antimycobacterial activity of 4-(5-substituted-1,3,4-oxadiazol-2-yl)pyridines. Bioorg. Med. Chem. 2007, 15, 5502–5508.
- Podust, L.M., Poulos, T.L., Waterman, M.R. Crystal structure of cytochrome P450 14alpha-sterol demethylase (CYP51) from *Mycobacterium tuberculosis* in complex with azole inhibitors. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 3068–3073.
- 22. Bellamine, A., Mangla, A.T., Nes, W.D., Waterman, M.R. Characterization and catalytic properties of the sterol 14alphademethylase from *Mycobacterium tuberculosis*. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 8937–8942.
- 23. Barnett, C.J. Exchange Amination Process for Preparing 2-Hydrazinobenzothiazoles. U.S. Patent 3,937,714.
- 24. Kumar, V., Roy, R.K., Kumar, V., Kukshal, A., Yadav, V.P. Synthesis and antimicrobial activity of 2-(6-substituted-1,3-benzothiazol-2-yl)-*N*-(4-halophenyl)hydrazinecarbothiomide. J. Indian Chem. Soc. 2008, 85B, 333–335.
- Rattan, A. Antimicrobials in Laboratory Medicine. New Delhi: Churchill BI Livingstone, 2000, pp. 85–108.
- 26. Anargyros, P., Astill, D.S., Lim, I.S. Comparison of improved BACTEC and Lowenstein-Jensen media for culture of mycobacteria from clinical specimens. J. Clin. Microbiol. 1990, 28, 1288–1291.
- 27. Shah, R.R., Mehta, R.D., Parikh, A.R. Studies on isoniazide derivatives: preparation and antimicrobial activity of 2-aryl-3-(pyridylcarbomyl)-5-carboxymethyl-4-thiazolidinones. J. Indian Chem. Soc. 1985, 62B, 255-257.
- 28. Desai, N.C., Shukla, H.K., Tahker, K.A. Some new 2-aryl-3isonicotamido-4-thiazolidinones and their 5-carboxymethyl homologues as potential antitubercular and antibacterial agent. J. Indian Chem. Soc. 1984, 61B, 239–240.